Trefis expects Bristol-Myers Squibb’s (NYSE:BMY) Cardiovascular Drugs Revenue to rise from $9.2 billion in 2020 to $11.4 billion in 2021 and to $12.6 billion in 2022.
- What’s Next For Bristol Myers Squibb Stock?
- What To Expect From Bristol Myers Squibb Stock After Q2 Results?
- Is There More Room For Growth In Bristol Myers Squibb Stock?
- What To Expect From Bristol Myers Squibb Stock After Q1 Results?
- Is There A Better Pick Over Philip Morris Stock?
- Bristol Myers Squibb Stock Is Likely To Offer Better Returns Over This Life Sciences Company
We expect sales growth to be driven partly by Eliquis, an anticoagulant.
Although the Oncology segment remains the biggest driver of BMY’s revenues, we think that Cardiovascular drugs will play an increasing role in driving the company’s revenues and profits in the coming years.
What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market since 2016